Annals ofRheumatoid Arthritis

Volume: 2 - Number: 8 - February 15, 2004

Outstanding

Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement

Rheumatoid Arthritis: Beyond the Lymphocyte

Rheumatoid Arthritis: Time for Trials of Therapeutic Targets

Rheumatoid Arthritis—A Molecular Understanding

Ankylosing Spondylitis

Novel Concepts of Severity Mechanisms in AS

Antiarthritics drugs

New guidelines issued for arthritis drugs

NSAID Toxicity: Where Are We and How Do We Go Forward?

NSAIDs and enantiomers of flurbiprofen target -secretase and lower Aß42 in vivo

Autoantibodies in rheumatics diseases

Giantin is the major Golgi autoantigen in human anti-Golgi complex sera

Autoimmunity

Multiple immuno-regulatory defects in type-1 diabetes

Experimental Arthritis

Inhibition of established collagen-induced arthritis with a tumour necrosis factor-? inhibitor expressed from a self-contained doxycycline regulated plasmid

Rheumatic fever–associated Streptococcus pyogenes isolates aggregate collagen

Immunodeficiency

Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways

Inflammation

Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-7

NF-kB: a key role in inflammatory diseases

Inflammatory polyarthritis

Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Mediators and inflammation

Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes

Neovascularization

Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1

Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles

Osteoarthritis

Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial

Periodics fever diseases

Hereditary Periodic Fever

Polimialgia and arteritis

Polymyalgia Rheumatica and Giant-Cell Arteritis

Rheumatoid Arthritis

Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement

Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56 bright, CD94bright, CD158negative phenotype

A randomized, controlled trial of interferon-?-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626627

Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy

Rheumatoid Arthritis: Beyond the Lymphocyte

Rheumatoid Arthritis: Time for Trials of Therapeutic Targets

Rheumatoid Arthritis—A Molecular Understanding

Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients

Rheumatoid Factors: What Do They Tell Us?

Therapeutics

Methotrexate: Vital New Information About a Middle Aged Drug

Tuberculosis and rheumatoid arthritis

Rheumatoid Arthritis and Tuberculosis: Time To Take Notice